Altimmune reported a net loss of $22.8 million, or $0.12 per share, for the second quarter ended June 30, 2026, compared to a $22.1 million loss in the prior year period. The company held $519 million in cash and investments as of June 30, 2026. Key clinical milestones included initiating the global Phase 3 PERFORMA trial for MASH, reporting positive topline data from the Phase 2 RECLAIM trial in AUD, and completing enrollment in the Phase 2 RESTORE trial for ALD. R&D expenses rose to $18.7 million due to startup costs for the PERFORMA trial and ongoing ALD work, while G&A expenses increased to $7.6 million. Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide for serious liver diseases.

On July 28, 2026, Altimmune announced positive topline results from the Phase 2 RECLAIM trial evaluating pemvidutide 2.4 mg for moderate to severe alcohol use disorder. The trial met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo (p=0.0014). Secondary endpoints included a two-level reduction in WHO Risk Drinking Levels (64.4% vs 34.8%, p=0.0049) and zero heavy drinking days (42.2% vs 17.4%, p=0.0066), both recognized by the FDA as registrational endpoints. The drug demonstrated a generally favorable safety profile, though nausea and vomiting were observed. Altimmune plans to request an End-of-Phase 2 meeting with the FDA and initiate a Phase 3 trial for MASH in Q3 2026. Altimmune is a late clinical-stage biopharmaceutical company developing therapies for serious liver diseases.

Altimmune, Inc. announced plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey, later this year. The company entered into a 5-year office lease agreement for the new location with annual rent payments of approximately $300,000. This move is intended to support talent attraction and long-term cost efficiencies. Altimmune, Inc. is a late-stage biopharmaceutical development company.